The earnings call was overwhelmingly positive, with significant achievements such as the successful launch of Vykat XR, strong financial performance, and broad payer coverage. While there are some concerns about future inventory and revenue normalization, the overall outlook remains strong.

Company Guidance -

Q3 2025

In the second quarter of 2025, Soleno Therapeutics reported a successful commercial launch of Vykat XR, the first FDA-approved treatment for hyperphagia in patients with Prader-Willi Syndrome (PWS). The drug was approved on March 26, 2025, and became available on April 14, ahead of schedule. The initial response from the PWS community was positive, with 646 patient start forms received by June 30, 2025, and 295 unique prescribers. The company achieved total net revenue of $32.7 million for the quarter, reflecting the high demand and effective launch efforts. Soleno's efforts to secure payer coverage were successful, with 33% of all insured lives covered across commercial, Medicaid, and Medicare channels. The company also reported a net loss of $4.7 million, with cash, cash equivalents, and marketable securities totaling $293.8 million at the end of the quarter, bolstered by an additional $230 million raised post-quarter through a stock offering. Soleno is actively working towards European market approval for DCCR, marketed as Vykat XR in the U.S., to expand its commercial reach.

Successful Launch of Vykat XR

The commercial launch of Vykat XR, the first FDA-approved medicine for hyperphagia in PWS, was ahead of schedule and received well by the community. Initial demand and steady growth in patient starts and unique prescribers were noted.

Strong Financial Performance

Total net revenue for the second quarter was $32.7 million, with a significant increase from $0 revenue in the same period in 2024. The company raised an additional $230 million, bringing the total cash balance to over $500 million.

Broad Payer Coverage

Approximately 33% of all insured lives are now covered, representing over 100 million lives in the U.S. This includes major insurers across commercial, Medicaid, and Medicare channels.

Progress in European Expansion

Submission and EMA validation of the marketing authorization application for DCCR in the EU were announced, aiming to expand the commercial market.

Lower Discontinuation Rates

Discontinuation rates for Vykat XR are substantially lower than those observed in clinical trials, indicating strong adherence.

Soleno Therapeutics (SLNO) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SLNO Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.06 / -	-1.83	―	―	―
Aug 06, 2025	2025 (Q2)	-0.45 / -0.09	-0.57	84.21% (+0.48)	―
May 07, 2025	2025 (Q1)	-0.97 / -0.95	-0.59	-61.02% (-0.36)	―
Feb 27, 2025	2024 (Q4)	-0.97 / -1.27	-0.33	-284.85% (-0.94)	―	―
Nov 06, 2024	2024 (Q3)	-0.60 / -1.83	-0.95	-92.63% (-0.88)	―	―
Aug 07, 2024	2024 (Q2)	-0.57 / -0.57	-0.81	29.63% (+0.24)	―	―
May 10, 2024	2024 (Q1)	-0.37 / -0.59	-0.88	32.95% (+0.29)	―	―
Mar 06, 2024	2023 (Q4)	-0.27 / -0.33	-0.58	43.10% (+0.25)	―	―
Nov 07, 2023	2023 (Q3)	-0.58 / -0.95	-0.76	-25.00% (-0.19)	―	―
Aug 08, 2023	2023 (Q2)	-0.83 / -0.81	-0.9	10.00% (+0.09)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SLNO Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$81.19	$78.71	-3.05%
May 07, 2025	$74.66	$76.26	+2.14%
Feb 27, 2025	$44.99	$48.82	+8.51%
Nov 06, 2024	$56.86	$57.11	+0.44%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Soleno Therapeutics Inc (SLNO) report earnings?

Soleno Therapeutics Inc (SLNO) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Soleno Therapeutics Inc (SLNO) earnings time?

Soleno Therapeutics Inc (SLNO) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SLNO EPS forecast?

SLNO EPS forecast for the fiscal quarter 2025 (Q3) is -0.06.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing